Teplitsky Liane Rae
Known title: Chief Operating OfficerCIK: 0002132552
Teplitsky Liane Rae's purchase track record
Teplitsky Liane Rae has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/26/2026 | PLSE | $200K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PLSE | ▲ Buy | Open Market | 1,001 | $50K | 9/1/2026 | View on chart |
| PLSE | ▲ Buy | Open Market | 1,024 | $50K | 8/31/2026 | View on chart |
| PLSE | ▲ Buy | Open Market | 1,034 | $50K | 8/28/2026 | View on chart |
| PLSE | ▲ Buy | Open Market | 1,036 | $50K | 8/26/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Pulse Biosciences Partners with Clayman Thyroid Center
Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.
Pulse Biosciences Partners with Clayman Thyroid Center. Pulse Biosciences announced a commercial and clinical partnership with the Clayman Thyroid Center in Tampa, Florida. Additionally, Oppenheimer raised its price target to $60 and maintained an Outperform rating, citing the importance of the 2027 trial readout for the company's new ablation modality. The stock recently saw a 12.3% rise following the completion of full enrollment for the NANOPULSE-AF trial.